Synta Pharmaceuticals (SNTA) 2.29 $SNTA
The New Leaner Synta Pharmaceuticals Has Upcoming Catalysts
Christopher F. Davis - at Seeking Alpha - Wed Feb 11, 5:41PM CST
SNTA: 2.29 (-0.03)
Biotech Stocks Technical Review -- Merrimack Pharma, Orexigen Therapeutics, Alkermes, Galena Biopharma, and Synta Pharma
PR Newswire - Wed Feb 11, 8:05AM CST
Editor Note: For more information about this release, please scroll to bottom.
MACK: 10.22 (+0.40), OREX: 5.55 (+0.10), SNTA: 2.29 (-0.03), GALE: 1.68 (+0.06), ALKS: 71.40 (-1.89)
Synta Outlines New Corporate Strategy
Business Wire - Thu Feb 05, 3:01PM CST
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today outlined a new corporate strategy aimed at focusing the Company's resources on achieving key value creating milestones in 2015 and 2016, and transforming the organization into a leading oncology biopharmaceuticals company.
SNTA: 2.29 (-0.03)
Synta to Present at the 17th Annual BIO CEO & Investor Conference
Business Wire - Tue Feb 03, 3:01PM CST
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the Company will present at the 17th Annual BIO CEO & Investor Conference on Tuesday, February 10th at 3:00 p.m. (ET) in New York.
SNTA: 2.29 (-0.03)
Lung Cancer Clinical Trial Overview 2014
M2 - Fri Jan 23, 9:13PM CST
Research and Markets (http://www.researchandmarkets.com/research/9ww7kn/lung_cancer) has announced the addition of the "Lung Cancer Clinical Trial Overview" report to their offering. This report provides insight into the current clinical trial activity surrounding lung cancer by examining industry-sponsored activities and quantifying important development milestones and trial metrics: - Phase of study - Study type distribution (expanded access, interventional, observational) - Length of trials - Patient enrollment - Study sponsors - Regional breakdown Major Sections: - Introduction - Lung Cancer Clinical Trial Analysis - Average Clinical Trial Enrollment - Study Sponsor Analysis by Phase - Regional Analysis How you can use this report: - Identify how products currently in development could impact this market and understand competitor involvement by using detailed information on current late phase lung cancer trials - Benchmark your study length and patient enrollment metrics against industry-wide, phase-specific, and study type-specific averages - Plan your clinical trial strategy better by understanding where industry-funded lung cancer trial sites are located globally Key Topics Covered: 1. Introduction 2. Lung cancer clinical trial analysis 3. Average length of clinical trials 4. Average Clinical Trial Enrollment 5. Study sponsor analysis by Phase 6. Regional analysis Companies Mentioned - Actavis - Agennix - Amgen - AstraZeneca - Betta Pharmaceuticals - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene Corporation - Chong Kun Dang Pharmaceutical - Eisai - Eli Lilly and Company - EMD Serono - Genentech - Gilead Sciences - GlaxoSmithKline - Helsinn Therapeutics (U.S.) - Hoffmann-La Roche - J. Uriach and Company - Janssen Korea - Jiangsu HengRui Medicine Co. - Kael-GemVax Co. - Merck KGaA - Novartis Pharmaceuticals - Peregrine Pharmaceuticals - Pfizer - Pierre Fabre Pharma GmbH - Sanofi - Swami Rama Cancer Hospital and Research Institute - Synta Pharmaceuticals - Teva Pharmaceutical Industries For more information visit http://www.researchandmarkets.com/research/9w...ung_cancer
AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), SNTA: 2.29 (-0.03), GILD: 101.90 (+1.10), TEVA: 56.77 (-0.58), CELGZ: 3.17 (-0.04), NVS: 102.20 (-0.17)
Technical Scrutiny on Biotech Stocks - Galena Biopharma, Synta Pharma, Merrimack Pharma, Vertex Pharma, and Spectrum Pharma
PR Newswire - Wed Jan 07, 7:55AM CST
Investor-Edge has initiated coverage on the following equities: Galena Biopharma Inc. (NASDAQ: GALE), Synta Pharmaceuticals Corporation (NASDAQ: SNTA), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), and Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, January 06, 2015, the NASDAQ Composite ended at 4,592.74, down 1.29%, the Dow Jones Industrial Average edged 0.74% lower, to finish the day at 17,371.64, and the S&P 500 closed at 2,002.61, down 0.89%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 788.11, down 0.27%, while the index has advanced 6.19% in the previous three months. Register for your complimentary reports on these five stocks at:
MACK: 10.22 (+0.40), VRTX: 113.66 (+4.03), SNTA: 2.29 (-0.03), SPPI: 7.20 (+0.15), GALE: 1.68 (+0.06)
My New Years Resolution: Balance My Risky Portfolio
Jack Banser - at Seeking Alpha - Mon Dec 29, 5:23PM CST
T: 34.66 (+0.05), SNTA: 2.29 (-0.03), F: 16.30 (-0.06), MSEX: 22.22 (-0.11), PFE: 34.64 (-0.23), JCP: 8.05 (+0.14), EOX: 1.15 (unch), DTV: 87.51 (-0.32), BAC: 16.61 (-0.06), TWTR: 48.50 (+0.55), FLO: 21.68 (+0.38), SIRI: 3.83 (-0.07), GTE: 2.83 (+0.08)
Synta Pharmaceuticals Down 8.2%, Shares Slide into the Red (SNTA)
Comtex SmarTrend(R) - Mon Dec 15, 11:36AM CST
Synta Pharmaceuticals (NASDAQ:SNTA) is one of today's worst performing low-priced stocks, down 8.2% to $2.63 on 1.2x average daily volume. Synta Pharmaceuticals has traded 1.2 million shares thus far today, vs. average volume of 996,000 shares per day. The stock has underperformed the Dow (-8.2% to the Dow's -0.4%) and underperformed the S&P 500 (-8.2% to the S&P's -0.3%) during today's trading.
SNTA: 2.29 (-0.03)
Update: Synta Pharmaceuticals Announces Phase I Results - The Good And The Bad
Christopher F. Davis - at Seeking Alpha - Fri Dec 12, 1:35PM CST
SNTA: 2.29 (-0.03)
Synta Announces Presentation of Results from an Investigator-Sponsored Phase 1 Trial of Ganetespib in HER2+ Metastatic Breast Cancer at the 2014 San Antonio Breast Cancer Symposium
Business Wire - Fri Dec 12, 7:00AM CST
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced presentation of preliminary results from an investigator-sponsored phase 1 trial, designed to evaluate ganetespib in combination with paclitaxel and trastuzumab in women with HER2+ metastatic breast cancer (MBC) refractory to other HER2 inhibitors. The results are being presented during a poster session at the 2014 San Antonio Breast Cancer Symposium in San Antonio, Texas.
SNTA: 2.29 (-0.03)
Update: Why Synta Pharmaceuticals' Inducement Awards To Management Helps Shareholders
Christopher F. Davis - at Seeking Alpha - Thu Dec 11, 3:54PM CST
SNTA: 2.29 (-0.03)
Synta Pharmaceuticals announces inducement awards to two new executives, Chen Schor and Marc Schneebaum
M2 - Thu Dec 11, 6:07AM CST
Biopharmaceutical company Synta Pharmaceuticals (NasdaqGM:SNTA) on Wednesday reported inducement awards to its new executive vice president and chief operating officer, Chen Schor, and its newly appointed senior vice president and chief financial officer, Marc Schneebaum.
SNTA: 2.29 (-0.03)
Synta Reports Inducement Grants to New Chief Operating Officer and New Chief Financial Officer
Business Wire - Wed Dec 10, 3:30PM CST
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the grant of inducement awards to its newly appointed Executive Vice President and Chief Operating Officer, Chen Schor, and its newly appointed Senior Vice President and Chief Financial Officer, Marc Schneebaum. The awards were approved by the Board's Compensation Committee and ratified by the full Board on December 1, 2014 as an inducement material to Mr. Schor and Mr. Schneebaum entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4). Both awards were approved subject to each officer's commencement of employment with the Company on December 8, 2014.
SNTA: 2.29 (-0.03)
Update: Synta Shakes Up Its Management Team
Christopher F. Davis - at Seeking Alpha - Fri Dec 05, 3:03PM CST
SNTA: 2.29 (-0.03)
Synta makes CFO change, appoints COO
Seeking Alpha - at Seeking Alpha - Thu Dec 04, 4:54PM CST
SNTA: 2.29 (-0.03)
Synta Strengthens Management Team with Two Executive Appointments
Business Wire - Thu Dec 04, 3:30PM CST
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the appointment of Chen Schor as the Company's Executive Vice President and Chief Operating Officer and Marc Schneebaum as the Company's Senior Vice President and Chief Financial Officer, both effective as of December 8, 2014. Mr. Schneebaum will be replacing Keith S. Ehrlich, who will be stepping down as the Company's Chief Financial Officer, effective as of December 8, 2014. Mr. Ehrlich will remain with the Company during a transition period. The two appointments bring significant financial, business development and operational experience in the biopharmaceutical industry to Synta.
SNTA: 2.29 (-0.03)
Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/cbhmvq/relapsed_acute) has announced the addition of the "Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Acute Myeloid Leukemia and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Relapsed Acute Myeloid Leukemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Relapsed Acute Myeloid Leukemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AbbVie - Actinium - Agios - Altor BioScience - Ambit Biosciences - Amgen - Astellas Pharma - Astex - AstraZeneca - AVEO - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - Conkwest - Cornerstone - CTI BioPharma - Eisai - EpiZyme - Exelixis - F. Hoffmann-La Roche - Fujifilm Corporation - Genoscience Pharma - GlaxoSmithKline - Igenica Biotherapeutics - Incyte - Jiangsu Hansoh Pharmaceutical - JW Pharmaceutical - Karyopharm Therapeutics - Kyowa Hakko Kirin Co., Ltd. - Les Laboratoires Servier SAS - MacroGenics, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Piramal Enterprises Limited - Plexxikon Inc. - Polaris Group - Seattle Genetics, Inc. - Sunesis Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Targa Therapeutics Corp. - Tolero Pharmaceuticals, Inc. - Verastem, Inc. For more information visit http://www.researchandmarkets.com/research/cb...psed_acute
MGNX: 34.09 (+0.10), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56), CTIC: 2.23 (-0.02), GSK: 47.94 (+1.99), VSTM: 7.93 (-0.44), SNTA: 2.29 (-0.03), SGEN: 31.57 (+0.36), MRK: 58.81 (-0.07), AMBI: 15.60 (+0.26), CELGZ: 3.17 (-0.04), KPTI: 27.12 (-0.13), NVS: 102.20 (-0.17)
Synta Announces Presentation on Hsp90 inhibitor Drug Conjugate Platform at 26th EORTC-NCI-AACR Symposium
Business Wire - Wed Nov 19, 6:00AM CST
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that a poster highlighting preclinical results from its Hsp90 inhibitor Drug Conjugate (HDC) platform is being presented at the 26th EORTC-NCI-AACR Symposium in Barcelona.
SNTA: 2.29 (-0.03)
Synta to Present at the Stifel 2014 Healthcare Conference
Business Wire - Wed Nov 12, 3:02PM CST
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the Company will present at the Stifel 2014 Healthcare Conference on Wednesday, November 19, at 2:25 p.m. (ET) in New York.
SNTA: 2.29 (-0.03)
Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - Mon Nov 10, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 2.45 (+0.28), CRIS: 3.23 (+0.25), IMMU: 3.84 (unch), PCYC: 163.28 (+0.23), ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), JNJ: 99.62 (+1.18), SNTA: 2.29 (-0.03), NVS: 102.20 (-0.17), XLRN: 38.02 (+0.07), ARRY: 8.05 (+0.08), CELGZ: 3.17 (-0.04), EXEL: 2.48 (+0.20)
The New Leaner Synta Pharmaceuticals Has Upcoming Catalysts
Christopher F. Davis - at Seeking Alpha - Wed Feb 11, 5:41PM CST
SNTA: 2.29 (-0.03)
Biotech Stocks Technical Review -- Merrimack Pharma, Orexigen Therapeutics, Alkermes, Galena Biopharma, and Synta Pharma
PR Newswire - Wed Feb 11, 8:05AM CST
Editor Note: For more information about this release, please scroll to bottom.
MACK: 10.22 (+0.40), OREX: 5.55 (+0.10), SNTA: 2.29 (-0.03), GALE: 1.68 (+0.06), ALKS: 71.40 (-1.89)
Synta Outlines New Corporate Strategy
Business Wire - Thu Feb 05, 3:01PM CST
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today outlined a new corporate strategy aimed at focusing the Company's resources on achieving key value creating milestones in 2015 and 2016, and transforming the organization into a leading oncology biopharmaceuticals company.
SNTA: 2.29 (-0.03)
Synta to Present at the 17th Annual BIO CEO & Investor Conference
Business Wire - Tue Feb 03, 3:01PM CST
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the Company will present at the 17th Annual BIO CEO & Investor Conference on Tuesday, February 10th at 3:00 p.m. (ET) in New York.
SNTA: 2.29 (-0.03)
Lung Cancer Clinical Trial Overview 2014
M2 - Fri Jan 23, 9:13PM CST
Research and Markets (http://www.researchandmarkets.com/research/9ww7kn/lung_cancer) has announced the addition of the "Lung Cancer Clinical Trial Overview" report to their offering. This report provides insight into the current clinical trial activity surrounding lung cancer by examining industry-sponsored activities and quantifying important development milestones and trial metrics: - Phase of study - Study type distribution (expanded access, interventional, observational) - Length of trials - Patient enrollment - Study sponsors - Regional breakdown Major Sections: - Introduction - Lung Cancer Clinical Trial Analysis - Average Clinical Trial Enrollment - Study Sponsor Analysis by Phase - Regional Analysis How you can use this report: - Identify how products currently in development could impact this market and understand competitor involvement by using detailed information on current late phase lung cancer trials - Benchmark your study length and patient enrollment metrics against industry-wide, phase-specific, and study type-specific averages - Plan your clinical trial strategy better by understanding where industry-funded lung cancer trial sites are located globally Key Topics Covered: 1. Introduction 2. Lung cancer clinical trial analysis 3. Average length of clinical trials 4. Average Clinical Trial Enrollment 5. Study sponsor analysis by Phase 6. Regional analysis Companies Mentioned - Actavis - Agennix - Amgen - AstraZeneca - Betta Pharmaceuticals - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene Corporation - Chong Kun Dang Pharmaceutical - Eisai - Eli Lilly and Company - EMD Serono - Genentech - Gilead Sciences - GlaxoSmithKline - Helsinn Therapeutics (U.S.) - Hoffmann-La Roche - J. Uriach and Company - Janssen Korea - Jiangsu HengRui Medicine Co. - Kael-GemVax Co. - Merck KGaA - Novartis Pharmaceuticals - Peregrine Pharmaceuticals - Pfizer - Pierre Fabre Pharma GmbH - Sanofi - Swami Rama Cancer Hospital and Research Institute - Synta Pharmaceuticals - Teva Pharmaceutical Industries For more information visit http://www.researchandmarkets.com/research/9w...ung_cancer
AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), SNTA: 2.29 (-0.03), GILD: 101.90 (+1.10), TEVA: 56.77 (-0.58), CELGZ: 3.17 (-0.04), NVS: 102.20 (-0.17)
Technical Scrutiny on Biotech Stocks - Galena Biopharma, Synta Pharma, Merrimack Pharma, Vertex Pharma, and Spectrum Pharma
PR Newswire - Wed Jan 07, 7:55AM CST
Investor-Edge has initiated coverage on the following equities: Galena Biopharma Inc. (NASDAQ: GALE), Synta Pharmaceuticals Corporation (NASDAQ: SNTA), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), and Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, January 06, 2015, the NASDAQ Composite ended at 4,592.74, down 1.29%, the Dow Jones Industrial Average edged 0.74% lower, to finish the day at 17,371.64, and the S&P 500 closed at 2,002.61, down 0.89%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 788.11, down 0.27%, while the index has advanced 6.19% in the previous three months. Register for your complimentary reports on these five stocks at:
MACK: 10.22 (+0.40), VRTX: 113.66 (+4.03), SNTA: 2.29 (-0.03), SPPI: 7.20 (+0.15), GALE: 1.68 (+0.06)
My New Years Resolution: Balance My Risky Portfolio
Jack Banser - at Seeking Alpha - Mon Dec 29, 5:23PM CST
T: 34.66 (+0.05), SNTA: 2.29 (-0.03), F: 16.30 (-0.06), MSEX: 22.22 (-0.11), PFE: 34.64 (-0.23), JCP: 8.05 (+0.14), EOX: 1.15 (unch), DTV: 87.51 (-0.32), BAC: 16.61 (-0.06), TWTR: 48.50 (+0.55), FLO: 21.68 (+0.38), SIRI: 3.83 (-0.07), GTE: 2.83 (+0.08)
Synta Pharmaceuticals Down 8.2%, Shares Slide into the Red (SNTA)
Comtex SmarTrend(R) - Mon Dec 15, 11:36AM CST
Synta Pharmaceuticals (NASDAQ:SNTA) is one of today's worst performing low-priced stocks, down 8.2% to $2.63 on 1.2x average daily volume. Synta Pharmaceuticals has traded 1.2 million shares thus far today, vs. average volume of 996,000 shares per day. The stock has underperformed the Dow (-8.2% to the Dow's -0.4%) and underperformed the S&P 500 (-8.2% to the S&P's -0.3%) during today's trading.
SNTA: 2.29 (-0.03)
Update: Synta Pharmaceuticals Announces Phase I Results - The Good And The Bad
Christopher F. Davis - at Seeking Alpha - Fri Dec 12, 1:35PM CST
SNTA: 2.29 (-0.03)
Synta Announces Presentation of Results from an Investigator-Sponsored Phase 1 Trial of Ganetespib in HER2+ Metastatic Breast Cancer at the 2014 San Antonio Breast Cancer Symposium
Business Wire - Fri Dec 12, 7:00AM CST
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced presentation of preliminary results from an investigator-sponsored phase 1 trial, designed to evaluate ganetespib in combination with paclitaxel and trastuzumab in women with HER2+ metastatic breast cancer (MBC) refractory to other HER2 inhibitors. The results are being presented during a poster session at the 2014 San Antonio Breast Cancer Symposium in San Antonio, Texas.
SNTA: 2.29 (-0.03)
Update: Why Synta Pharmaceuticals' Inducement Awards To Management Helps Shareholders
Christopher F. Davis - at Seeking Alpha - Thu Dec 11, 3:54PM CST
SNTA: 2.29 (-0.03)
Synta Pharmaceuticals announces inducement awards to two new executives, Chen Schor and Marc Schneebaum
M2 - Thu Dec 11, 6:07AM CST
Biopharmaceutical company Synta Pharmaceuticals (NasdaqGM:SNTA) on Wednesday reported inducement awards to its new executive vice president and chief operating officer, Chen Schor, and its newly appointed senior vice president and chief financial officer, Marc Schneebaum.
SNTA: 2.29 (-0.03)
Synta Reports Inducement Grants to New Chief Operating Officer and New Chief Financial Officer
Business Wire - Wed Dec 10, 3:30PM CST
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the grant of inducement awards to its newly appointed Executive Vice President and Chief Operating Officer, Chen Schor, and its newly appointed Senior Vice President and Chief Financial Officer, Marc Schneebaum. The awards were approved by the Board's Compensation Committee and ratified by the full Board on December 1, 2014 as an inducement material to Mr. Schor and Mr. Schneebaum entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4). Both awards were approved subject to each officer's commencement of employment with the Company on December 8, 2014.
SNTA: 2.29 (-0.03)
Update: Synta Shakes Up Its Management Team
Christopher F. Davis - at Seeking Alpha - Fri Dec 05, 3:03PM CST
SNTA: 2.29 (-0.03)
Synta makes CFO change, appoints COO
Seeking Alpha - at Seeking Alpha - Thu Dec 04, 4:54PM CST
SNTA: 2.29 (-0.03)
Synta Strengthens Management Team with Two Executive Appointments
Business Wire - Thu Dec 04, 3:30PM CST
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the appointment of Chen Schor as the Company's Executive Vice President and Chief Operating Officer and Marc Schneebaum as the Company's Senior Vice President and Chief Financial Officer, both effective as of December 8, 2014. Mr. Schneebaum will be replacing Keith S. Ehrlich, who will be stepping down as the Company's Chief Financial Officer, effective as of December 8, 2014. Mr. Ehrlich will remain with the Company during a transition period. The two appointments bring significant financial, business development and operational experience in the biopharmaceutical industry to Synta.
SNTA: 2.29 (-0.03)
Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/cbhmvq/relapsed_acute) has announced the addition of the "Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Acute Myeloid Leukemia and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Relapsed Acute Myeloid Leukemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Relapsed Acute Myeloid Leukemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AbbVie - Actinium - Agios - Altor BioScience - Ambit Biosciences - Amgen - Astellas Pharma - Astex - AstraZeneca - AVEO - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - Conkwest - Cornerstone - CTI BioPharma - Eisai - EpiZyme - Exelixis - F. Hoffmann-La Roche - Fujifilm Corporation - Genoscience Pharma - GlaxoSmithKline - Igenica Biotherapeutics - Incyte - Jiangsu Hansoh Pharmaceutical - JW Pharmaceutical - Karyopharm Therapeutics - Kyowa Hakko Kirin Co., Ltd. - Les Laboratoires Servier SAS - MacroGenics, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Piramal Enterprises Limited - Plexxikon Inc. - Polaris Group - Seattle Genetics, Inc. - Sunesis Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Targa Therapeutics Corp. - Tolero Pharmaceuticals, Inc. - Verastem, Inc. For more information visit http://www.researchandmarkets.com/research/cb...psed_acute
MGNX: 34.09 (+0.10), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56), CTIC: 2.23 (-0.02), GSK: 47.94 (+1.99), VSTM: 7.93 (-0.44), SNTA: 2.29 (-0.03), SGEN: 31.57 (+0.36), MRK: 58.81 (-0.07), AMBI: 15.60 (+0.26), CELGZ: 3.17 (-0.04), KPTI: 27.12 (-0.13), NVS: 102.20 (-0.17)
Synta Announces Presentation on Hsp90 inhibitor Drug Conjugate Platform at 26th EORTC-NCI-AACR Symposium
Business Wire - Wed Nov 19, 6:00AM CST
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that a poster highlighting preclinical results from its Hsp90 inhibitor Drug Conjugate (HDC) platform is being presented at the 26th EORTC-NCI-AACR Symposium in Barcelona.
SNTA: 2.29 (-0.03)
Synta to Present at the Stifel 2014 Healthcare Conference
Business Wire - Wed Nov 12, 3:02PM CST
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the Company will present at the Stifel 2014 Healthcare Conference on Wednesday, November 19, at 2:25 p.m. (ET) in New York.
SNTA: 2.29 (-0.03)
Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - Mon Nov 10, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 2.45 (+0.28), CRIS: 3.23 (+0.25), IMMU: 3.84 (unch), PCYC: 163.28 (+0.23), ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), JNJ: 99.62 (+1.18), SNTA: 2.29 (-0.03), NVS: 102.20 (-0.17), XLRN: 38.02 (+0.07), ARRY: 8.05 (+0.08), CELGZ: 3.17 (-0.04), EXEL: 2.48 (+0.20)
